Exergy Power Systems, Inc. is a startup company from the University of Tokyo that provides IoT solutions to flexibly adjust sudden fluctuations of the electricity originated from renewable energy. Electricity generated from solar power and wind power always fluctuates under the influence of clouds and wind. As the proportion of renewable energy increases in the power system, conventional methods of preventing a sudden loss of renewable energy output can no longer be used. The company developed a new way of dealing with sudden fluctuations and provides a solution as a flexibility service. Flexibility services are especially needed in countries and regions that are engaged in energy transition from fossil resources to renewable resources. The company develops and manufactures next-generation energy storage systems which utilize proprietary storage batteries. The company’s storage battery has excellent rapid charge/discharge characteristics and durability, and can stabilize the power system when renewable energies are introduced into the power grid. Currently, MW-class energy storage system demonstration project is underway in Europe and Hawaii.

Our product is called “Toletta®” it is a smart IoT cat litter box that has different layers to separate urine and feces for easier and more convenient clean up. This system also ideal for detecting any abnormalities in your cat’s health that may not be directly noticeable, such as Chronic Kidney Disease. Chronic Kidney Disease is an incurable disease that affects 30% of the whole cat population, it is also tone of the leading causes in cat death. Early symptoms of this disease include an increased urine volume and decreased body weight, which toletta can measure simultaneously. We can also distinguish between various cats via our camera/face recognition technology, and all of your specific cat’s information will be available on our app, which makes our product more convenient for those who lead busy lives like those in the workforce or those who have limited energy to take care of their pet, such as the elderly. Our technology is very unique and innovative to the pet industry because we can help provide early detection, which leads to early treatment to one’s cat, which can prolong their lives so that everyone can live a happy cat life.

Metcela Inc. is a pre-clinical stage biotech startup in Japan. At Metcela, we are developing an innovative, clinically viable and efficacious cell therapy for chronic heart failure using a specific type of fibroblasts found in the heart, called “VCFs” or VCAM-1-positive cardiac fibroblasts. The effects of VCFs in cardiac function have been demonstrated in various animal heart failure models. VCF’s main function is to modify the microenvironment of the infarcted heart to promote survival and proliferation of pre-existing cardiac cells. Unlike many other technologies, our approach is to simply yet truly regenerate the cells that already exist in the heart and help them thrive in a more favorable environment that VCFs create.

　For cell delivery, we have teamed up with a leading catheter manufacturer in Japan to develop a unique injection catheter system which can assist the clinicians to precisely inject VCF to the infarcted areas. Combining the novel characteristics of VCFs and a cutting-edge technology of the precision delivery catheter, we are preparing to initiate an investigator-initiated phase I clinical trial in Japan in early 2021 and later bring the technology to other parts of the world.

Legislation of medical Device traceability will start in the United States in 2020 first and EU and other countries will follow.
Medical professionals pay attention to surgical instrument traceability issue in various countries including Japan as it contributes to patient safety in the end.

Looking at objective of tracability, some Japanese medical professionals misunderstand it as “Identification of indivisual surgical instrument” through barcode but it should include “evaluation of surgical instrument condition (cleaness, functionality and deterioration)” to avoid surgical site infection to the patients. Our goal is realizing quantitaive evaluation system of surgical instrument condition to contribute patient safety.

At Lifeform AI we create IoT interfaces for healthier habits. The LifeChair is our IoT platform that uses our patented eTextile sensing technology and AI-based human behaviour models to improve the quality of life at work and in the home. The LifeChair IoT cushion and its partner app train healthy habits through posture training, stretching guidance and tailored work-life balance management. We’ve partnered with Fujitsu to create the offices of tomorrow by using the LifeChair to provide a suite of wellness features and AI-powered personalised feedback. Our innovations have also sought new ways to assist those working remotely and from home by offering an in-home wellness platform for employees and team management tools for employers.

Onikle is the preprint search platform with the simple UIUX and AI recommendation to help scientists discover best papers. In addition to AI recommendation, users can follow and create Chronicle – research specialised bookmark – to find what other top scientists are reading and be updated to trending papers. With these features above, we have successfully reduced the search time up to 80%.
Onikle currently has 3000 Monthly active users from tech companies such as Facebook, IBM, and Amazon and users spend 3 times longer than the exisitng service, and MAU is increasing double per month.
Onikle will be monetised with 3 business models, which is highly targeted advertisement, $10 monthly subscription, and Recruitment model and has the potential to reach $1.2billion dollars with 10 million potential users from all over the world.
Google and Amazon believed that the Internet would become the world’s infrastructure even before it became widespread, and expanded their market share at an overwhelming speed. Onikle believes that preprints will become the infrastructure of the world, and we will grab our market share at an overwhelming speed. We create global platform that drives the knowledge of mankind.

Red Arrow Therapeutics’ chemists shape the behavior of proteins by carefully designing polymer-protein conjugates with controlled architecture, composition, size and stimuli responsive chemistry. Our unique approach can then generate prodrug-like proteins with optimal pharmacokinetics, biodistribution and targeted activation at disease sites without compromising the biological action of the proteins. With our novel platform, a broad range of valuable functional attributes will become accessible for therapeutic innovation. As a 1st pipeline, we focused on immunotherapy, where only 20% patients respond to standard immunoncological options, such as immune checkpoint inhibitors (ICIs). Because the immunosuppressive environment of cold tumors is the major reason for immunotherapy failure, Red Arrow Therapeutics has developed protein prodrugs that safely boost antitumor immunity. To this end, we have identified the hit formulation capable of tumor eradication, even in malignancies that are resistant to ICIs, and we will optimize this formulation before large-scale manufacturing, pre-clinical trials and clinical trials. We are convinced that our proprietary platform will attract Japanese investors and pharmaceuticals to jointly develop products, and we aim to achieve IPO with our pipelines toward blockbuster drugs and alliances.

PLIMES Inc. is a university spin-off company launched to create a pathway to market for academic research innovations originating from the research achievements at the Artificial Intelligence Laboratory, Center for Cybernics Research and Center for Innovative Medicine and Engineering at the University of Tsukuba, Japan.
PLIMES Inc. is managed by the cofounders Kenji Suzuki, PhD(Eng.), Tomoya Shimokakimoto, PhD(Eng.) and MSc (Med. Sc.), Dushyantha Jayatilake, PhD(Eng.) who each have over 15 years of experience in developing healthcare/robotics technologies and Atsushi Nitasaka (CEO of ZINE), who has experience in launching successful startups and the know-how to reach out using modern media strategies. In addition, we have a comprehensive board of medical advisors to accurately shape the technology to match the need. We are social enablers and PLIMES Inc. focuses on the social problem-solving business by operating to dramatically enhance user experience and social interaction for people with special needs. We spent over 10 years in the academia developing these fundamental technologies that are finally ready to be transferred to the society.